Ahmed Subahi, MD
Interventional Cardiology · Mobile, ALNPI 1780137927
Payments from drug & device makers
What this record shows
This record is dominated by grants: $33,333 of the $37,390 with a category attached, or 89.1%. Medtronic accounts for 90.5% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2023 at $34,981 and has fallen 98.5% since, to $534 in 2025.
Across 129 payments — averaging $289.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$34K
- Boston Scientific$1K
- Biotronik Inc.$567
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$370
- Edwards Lifesciences$258
- Abbott$252
- plus $905 from 17 others
Across 1 payment — averaging $49.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abiomed$50
What the payments were for
- Grants$33,33389%
- Travel & lodging$9202%
- Food & beverage$2,4997%
- Education$6382%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 39 | $33,827 |
| Boston Scientific | 6 | $1,212 |
| Biotronik Inc. | 4 | $567 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 21 | $370 |
| Edwards Lifesciences | 6 | $258 |
| Abbott | 12 | $252 |
| AstraZeneca | 7 | $208 |
| Amgen | 9 | $164 |
| Alnylam Pharmaceuticals Inc. | 3 | $103 |
| E.r. Squibb & Sons, L.L.C. | 4 | $65 |
| Pfizer | 4 | $62 |
| Lantheus Medical Imaging, Inc. | 2 | $42 |
| Abiomed | 2 | $37 |
| Sobi, Inc | 1 | $37 |
| Heartflow, Inc. | 1 | $25 |
| Kestra Medical Technology Services, Inc. | 1 | $25 |
| Novo Nordisk | 1 | $24 |
| Lilly USA, LLC | 1 | $24 |
| Akcea Therapeutics, Inc. | 1 | $23 |
| Nxstage Medical, Inc. | 1 | $19 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Novartis | 1 | $16 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$33,333
- WATCHMAN Access System$1,125
- Edora$459
- Acticor$459
- Solia$459
- Rivacor$459
- BioMonitor$459
- FARXIGA$125
- Micra$112
How this compares
$37,390 in reported general payments places this provider in the 85th percentile of 109 interventional cardiology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 12 | $99 |
| ClopidogrelClopidogrel Bisulfate | 12 | $93 |
| Losartan Potassium | 13 | $68 |
| Metoprolol Tartrate | 11 | $66 |
| Metoprolol Succinate | 11 | $50 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Mobile
- John GallaMobile$82K
- Mir HashimiMobile$24K
- Mohammed ElzeneiniMobile$23K
- Benjamin CitrinMobile$11K
- James GladdenMobile$9K
- Stanley ThorntonMobile$7K
- Michael MonsonMobile$7K
- Kevin DeandradeMobile$7K
- Gary RoubinBirmingham$157K
- Michael ButlerHuntsville$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.